Table 3.
Patient tumor/PDX doxorubicin/cyclophosphamide (AC) or epirubicin/cyclophosphamide (EC) response concordance analysis
| Patient Number (Arbitrary) | PDX | Clinical Setting | Patient Treatment | Clinical Response | PDX AC Response | AC/EC Patient Concordance? |
|---|---|---|---|---|---|---|
| 32 | BCM-0046 | Neo | EC | PR | PD | No |
| 33 | BCM-2665 | Neo | AC | PR | PD | No |
| 34 | BCM-3469 | Neo | AC | PR | PD | No |
| 35 | BCM-3936 | Neo | AC | PR | PD | No |
| 36 | BCM-15006/15046 | Neo | AC | PR | PR | Yes |
| 23 | WHIM2 | Neo | AC→Paclitaxel | PR | PR | Yes |
| 24 | WHIM14 | Neo | EC (w/ 5FU)→Docetaxel | PR | PR | Yes |
| 38 | WHIM6 | Neo | EC (with 5FU) | PR | PR | Yes |
| 40 | WHIM30 | Neo | AC (with paclitaxel)→ddAC | CR | PR | Yesa |
a
- PR and CR are adjacent RECIST 1.1 classifications.